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Abstract
Background: Among children diagnosed to have chronic rheumatic valvular heart disease (RHD) in Ethiopia, many
have been observed to develop recurrence of rheumatic fever (RF) despite secondary prophylaxis. This study
determined the throat culture positivity rate and drug susceptibility pattern of beta hemolytic streptococci (BHS)
isolated from children attending a specialized cardiac clinic in Ethiopia.
Methods: Throat swabs were collected from 233 children receiving benzathine penicillin injection as secondary
prophylaxis for RHD and cultured. The bacterial isolates were characterized using Matrix Assisted Laser Desorption/
Ionization-Time of Flight (MALDI-TOF) mass spectrometry. Drug susceptibility was tested with the Kirby Bauer disc
diffusion method. Anti-streptolysin O (ASO) titers were determined using ASO latex reagents.
Results: The throat culture positivity rate for BHS was 24 % (56/233). Among the BHS bacterial strains isolated, four
were characterized as S. pyogenes and another four as S. dysgalactiae subsp. equisimilis (Lancefield group A, C and
G). All BHS were susceptible to penicillin except one isolate of S. agalactiae. Among 233 children enrolled, 46(19.7 %)
showed increased ASO titer. Children who received antibiotic prophylaxis within 2-weeks of last injection had
significantly lower BHS throat culture positivity rate than those injected every 4-weeks (p = 0.02). Children who missed
at least one prophylaxis within the last 6 months had a higher BHS culture positivity rate than those who did not miss
any (p = 0.0003).
Conclusions: The presence of groups A, C and G streptococci in the throat of children under secondary prophylaxis
for RHD and increased ASO titer suggests failure of the regimen. This calls for further investigation into the causes of
inadequate prophylaxis (including bioavailability of drugs used, optimal duration and patient compliance) and
intervention.
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Background
Rheumatic fever (RF) is a non-suppurative, auto-
inflammatory multi-system response following infection
by group A beta hemolytic streptococci (BHS) also known
as Streptococcus pyogenes [1]. Streptococcus dysgalactiae
subsp. equisimilis expressing Lancefield group A (GAS), C
(GCS) or G (GGS) antigen is phylogenetically related to S.
pyogenes. It has recently emerged as a potential pathogen
and there is concern that it might cause human infections
similar to S. pyogenes including RF [2–5]. Eleven non-
group A-BHS strains have previously been recovered from
RF and/or rheumatic valvular heart disease (RHD)
patients in Ethiopia [6].
Rheumatic heart disease is the most dreaded complica-
tion of recurrent RF. Unless treated, the valve damage
can eventually lead to chronic intractable heart failure
and premature death. In developing countries, facilities
for this treatment are almost non-existent [7]. Although
its incidence is decreasing in industrialized countries,
RHD remains a major challenge in the rest of the world.
The highest prevalence is in sub-Saharan Africa with a
rate of 5.7 per 1000, compared to 1.8 per 1000 in North
Africa, and 0.3 per 1000 in economically advanced coun-
tries [8]. In Ethiopia, RHD is the number one cardiac
problem in children with a prevalence rate of 4.6–7.1
per 1000 [9, 10]. Data from hospitals indicate that about
one third [32.8 % (256/781) [11] and 39.2 % (127/324)
[12]] of heart disease cases are due to RHD. Among 457
cardiovascular deaths including cerebrovascular acci-
dents (CVA) from January 1995 to December 2001 in
the current study site, TikurAnbessa Specialized
Hospital (TASH), 26.5 % (121) were due to RHD [13].
Güntheret al. also reported 125.3 per 1000 person-year
mortality rate during 7 years of follow up of RHD pa-
tients at Dabat Health Centre in North Gondar, which
amounted to 12.5 % annual mortality rate among RHD
patients seen in this community [14].
The economic effects of the disability and premature
death caused by these diseases are felt at both the indi-
vidual and national levels through increased direct and
indirect health care costs. The most cost effective ap-
proach for the control of RHD is secondary prophylaxis
with penicillin injection every 3 or 4-weeks [14]. Careful
penicillin delivery results in recurrence prevention also
in high risk areas [15]. However, in our study setting in
Ethiopia, implementation of secondary antibiotic preven-
tion is challenged by missed opportunities for treatment,
poor access to health care and inadequate treatment of
tonsillopharyngitis with failure to eradicate S. pyogenes
from the throat [14, 16]. Therefore, we investigated the
throat culture positivity rate, BHS strain types and anti-
biotic susceptibility patterns and their relations to dose
intervals of penicillin in children on secondary prophy-
laxis for RHD at TASH.
Methods
Study design and population
Two hundred and thirty-three children who were on
secondary prophylaxis for RHD were enrolled in the
study. The participants were recruited consecutively as
they came to the cardiac clinic for their follow up ap-
pointment. The study was conducted at the Pediatric
Cardiac Clinic of TASH in Addis Ababa, Ethiopia, be-
tween July 2013 and June 2014.
Ethical clearance was obtained from the Ethics Review
Committees of the College of Health Sciences, Addis
Ababa University and the Armauer Hansen Research
Institute/All African Leprosy Rehabilitation and Training
Centre (AHRI/ALERT). Written informed consent was
obtained from each child’s parent or guardian and assent
from study participants older than 12 years. Parents/
guardians consented to sending bacterial isolates for typ-
ing at the Oslo University Hospital, University of Oslo,
Norway. Sample export permission was obtained from
the Ethiopian Institute of Biodiversity and the Oslo
University Hospital, University of Oslo, approved the
analysis of the bacterial isolates.
Socio-demographic, risk factors, clinical and laboratory data
General socio-demographic characteristics and risk
factors for the spread of BHS including assessment of
adherence to penicillin intake were collected by a struc-
tured questionnaire. Additional laboratory and clinical
data were collected from patient records.
Sample collection and processing
Throat swab samples were collected by trained nurses.
The tonsillar fauces and the posterior pharyngeal wall
behind the uvula were swabbed using sterile swab
applicators (Thermo Fisher Scientific, USA). Each swab
was immersed into a test tube containing skim milk-tryp-
tone-glucose-glycerin (STGG) medium (Thermo Fisher
Scientific, USA). The samples were stored at +4 °C and
transported to the AHRI bacteriology laboratory within
8 h. Two ml of venous blood was aseptically collected
from each study participant and serum stored at -80 °C.
Anti-streptolysin O (ASO) latex reagents (LiNEAR
Chemicals. s. L, Spain) were used to determine ASO titer
according to manufacturer’s recommendations.
Isolation and characterization of ß-hemolytic streptococci
The throat swabs were streaked on 7 % defibrinated
sheep blood agar plates (Becton, Dickinson, USA) and
incubated under CO2 at 37 °C for 24–48 h. ß-hemolytic
colonies were subcultured, and the isolates were tested
with catalase test, Gram stain, and bacitracin susceptibil-
ity test. All catalase-negative Gram-positive cocci were
stored in STGG media at -80 °C and transported to the
University of Oslo on dry ice for further characterization.
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All BHS isolates were serogrouped by a streptococcal
grouping latex kit (Pro-Lab Diagnostics, USA) according
to the manufacturer’s instructions.
Matrix-assisted laser desorption/ionization-time of
flight (MALDI-TOF) mass spectrometry (MS) analyses
was performed at the University of Oslo by the direct
colony method by using the Microflex mass spectrom-
eter (BrukerDaltonics, Germany) for species differenti-
ation. Streptococcal strains isolated from throat swabs
were re-cultivated on 5 % human blood agar media. A
1 μL inoculation loop full of each of the bacterial isolates
was obtained from a fresh culture, deposited in duplicate
on the target plate and smeared. The bacterial film was
first overlaid with 1 μL formic acid (100 %) and then
with 1 μL matrix α-cyano-4-hydroxycinnamic acid
(HCCA). Two spots were prepared for each bacterial iso-
late. The target plate was inserted into the Microflex mass
spectrometer and the spectra generated were analyzed by
the MALDI Biotyper 3.0 software (BrukerDaltonics,
Germany) and matched to the Biotyper 3.0 database.
All BHS were tested for susceptibility to commonly
used antibiotics with the disk diffusion method on
Mueller Hinton Agar (MHA) (Thermo Fisher Scientific,
USA) supplemented with 5 % defibrinated sheep blood
using standard methods. The BHS were tested against
the following antibiotics: penicillin G (10 units), oxacillin
(1 μg,), ceftriaxone (30 μg), vancomycin (30 μg), erythro-
mycin (15 μg), tetracycline (30 μg), ofloxacin (5 μg),
chloramphenicol (30 μg), clindamycin (2 μg), quinopristin-
dalfopristin (15 μg), linezolid (30 μg), and trimethoprim-
sulfamethoxazole (25 μg). Test interpretation was done
according to the Clinical Laboratory Standards Institute
(CLSI) [17].
Data management and analysis
Data was entered and summarized using SPSS version
20 software (USA) and analyzed using the STATA soft-
ware (StataCorp LP, College. Station, Texas, USA). Com-
parisons were made using the Chi—square test. A
p-value of ≤ 0.05 was considered indicative of a statisti-
cally significant difference.
Results
Socio-demographic characteristics of the study
participants
Two hundred and thirty-three children in the age range
of 5–15 years who were on secondary prophylaxis for
RHD participated in this study. Three-fourths of them
were aged between 10 and 15 years and girls accounted
for 59.1 %. All of the participants were on monthly peni-
cillin G prophylaxis. The most common valve lesions
observed in the children were mitral regurgitation
(92.3 %), tricuspid regurgitation (67.0 %) and aortic re-
gurgitation (54.1 %). Eighty-nine (38.2 %) participants
had been referred for possible surgical interventions, but
only three had received this treatment.
Frequency of beta-hemolytic streptococcal culture
positivity in children under prophylaxis
A total of 58 BHS were isolated from fifty-six partici-
pants. The throat culture positivity rate of BHS was
24 % (56/233). GAS occurred in 2.6 % (6/233) and
accounted for 10.3 % of the BHS (6/58). Twenty-five
(43.1 %) of the BHS belonged to serogroup F, 22
(37.9 %) to serogroup G, 2 to serogroup C, 1 to group B
and 2 could not be allocated to any type. In addition to
conventional characterization, all streptococcal strains
were identified to the species level by MALDI-TOF MS
(Table 1). The majority of the isolates belonged to S.
anginosus (36.2 %) and S. constellatus (43.1 %). S.
pyogenes and S. dysgalactiae subsp. equisimilis accounted
for 6.9 % each, while 5.2 % could not be classified.
Among the 6 group GAS isolates, four were bacitracin-
susceptible S. pyogenes and the other 2 were bacitracin-
resistant S. dysgalactiae subsp. equisimilis. S. dysgalactiae
subsp. equisimilis strains expressing either Lancefield group
A, C or G were detected in this study.
Speciation of 41 isolates which were difficult to distin-
guish as either α or β hemolytic on sheep blood agar
plates showed that the majority were either S. parasan-
guinis or S. mitis (31.7 % each). S. oralis, S. pneumoniae,
S. constellatus, and S. perioris accounted for 7.3, 4.9, 2.4,
and 2.4 % of these strains, respectively. However, 19.5 %
bacitracin-susceptible isolates could not be classified fur-
ther. Most S. parasanguinis (84.6 %) and about half of S.
mitis (54.5 %) were similarly bacitracin-sensitive. One
single a-hemolytic S. constellatus isolate was found to
possess Lancefield group C antigen.
Table 1 Species and serogroup distribution of beta hemolytic
streptococci isolated from children with rheumatic heart disease
Species Serogroup No %






S. agalactiae B 1 1.7
S. anginosus G 20 34.5
non-typeable 1 1.7
S. constellatus F 24 41.2
non-typeable 1 1.7
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Antibiotic susceptibility
All BHS isolates were susceptible to penicillin except for
one strain of S. agalactiae. This isolate was also resistant
to tetracycline, oxacillin, ceftriaxone, and vancomycin.
All four S. pyogenes isolates were susceptible to penicillin
and vancomycin. One isolate of S. pyogenes was resistant
to erythromycin and another intermediately resistant.
Overall, the sensitivity of BHS to erythromycin was 87 %
(48/55 tested). All BHS were non-susceptible to oxacil-
lin, and almost half of them (46.3 %) were also non-
susceptible to ceftriaxone.
Anti-streptolysin O titer
Among 233 participants, 69 (29.6 %) had a positive ASO
titer (≥200 IU/ml). Of these, 66.7 % (46/69) had ASO >
200 IU/ml, suggesting recent infection. The prevalence
of an increased ASO titer was 19.7 %. Out of 8 children
who had S. pyogenes or S. dysgalactiae in their throat
culture, 6 had ASO titer ≥ 200 IU/ml, indicating an ac-
tive infection. There was a statistically significant associ-
ation between BHS culture positivity and ASO positivity
(p = 0.0315) (Table 2). Among 56 patients for whom spe-
cies and serogroups could be determined, 23 were posi-
tive for ASO titer (Figs. 1 and 2).
Relationship between isolation of BHS from the throat
and antibiotic use
Participants missing prophylaxis had a higher likelihood
of having BHS in their throat (p = 0. 0003) (Table 3).
Children who received antibiotic prophylaxis at intervals
of between 22 and 28 days had 1.6 times higher risk to
have been colonized by BHS than those receiving
prophylaxis at intervals of ≤16 days (p = 0. 02, OR = 2.6,
CI =1. 16–5.85) (Table 4). Children who received anti-
biotic prophylaxis at an interval of ≥ 29 days had a 2.6
times higher risk of BHS colonization (p = 0.003, OR = 3.
61, CI = 1.5–8.46).
Of three participants who had S. pyogenes, two of
them had received their last dose more than 16 days be-
fore but one had the last injection less than 16 days ago.
In the same way, among 3 participants who had S. dys-
galactiae subsp. equisimilis, two had received injection
at an interval of more than 16 days and only one less
than 16 days ago.
Discussion
This study was carried out to determine the effectiveness
of secondary antibiotic prophylaxis in eliminating GAS
and other BHS from the throat of children with RHD
under follow-up at a pediatric cardiac clinic of a tertiary
hospital. Almost one quarter of the children (24 %) were
culture positive for BHS in their throat, and 20 % had in-
creased ASO titer suggesting active infection. Children
who received antibiotic prophylaxis within 2-weeks of
last injection had significantly lower BHS culture positiv-
ity rate than those injected every 4-weeks (p = 0. 02).
Children who missed at least one prophylaxis injection
within the last 6 months had a higher BHS culture posi-
tivity rate than those who did not miss any (p = 0.0003).
Defaulting from regular follow up is a strong contribu-
tor to mortality from RHD [14]. Four-week intervals of
injections would be expected to have less defaulting
rates than 3-week intervals. On the other hand, two-
weekly and three-weekly intramuscular penicillin injec-
tions have been reported to perform better in reducing
the recurrence of streptococcal throat infections and epi-
sodes of RF with higher concentration of penicillin in the
serum when compared to four-weekly injection [18, 19].
Table 2 Relationship between ASO titer and BHS infection in
children on antibiotic prophylaxis for RHD
ASO (titer ≥200 IU/ml) P-
valuePositive Negative Total
BHS isolated 23 33 56 0.0315
BHS negative 46 131 177











S. pyogenes S. dysgalactiae S. anginosus S. constellatus S. agalactiae Non-typable
ASO positive ASO negative
Fig. 1 Distribution of BHS species and ASO titer among children on










Group A Group G Group C Group F Group B non-typable
ASO positive ASO negative
Fig. 2 ASO titer and BHS serogoup distribution among children on
secondary antibiotic prophylaxis for RHD
Zegeye et al. BMC Infectious Diseases  (2016) 16:510 Page 4 of 8
The World Health Organization (WHO) and the
American Heart Association both recommend a three-
weekly regimen for individuals living in a high risk area
[20, 21]. Although Ethiopia is a high risk area for RHD,
the current regimen for secondary antibiotic prophylaxis
in Ethiopia is a four- weekly administration of intramuscu-
lar penicillin G injections.
Among 230 patients, 30.9 % had a history of docu-
mented recurrence of RF which is comparable to a study
conducted in a Pacific island population (38. of 144 par-
ticipants) (p = 0. 145) [22]. Rheumatic heart disease
frequency is higher in females (59.1 %), which is in
agreement with population and hospital based studies
conducted in Ethiopia and elsewhere [6, 23]. Eighty-nine
(38.2 %) were referred for possible surgical intervention
of which only three participants received this interven-
tion. A delay in surgical intervention for more than
1 year was observed in 46.5 % (40/86) of cases. This
delay of heart valve surgical intervention for more than
1 year was comparable with what it was like in Egypt
15-years ago [23].
In the current study, 29.6 % of the participants were
positive for ASO and 20 % showed increased ASO titer
indicating recent streptococcal infections. There was a
statistically significant association between BHS culture
positivity rate and ASO positivity, also considering pa-
tient age [24]. BHS expressing Lancefield group A, C
and G infections are reported to cause a rise in ASO
titer in serum [25–27]. This argues for infection rather
than simple colonization.
The reason for a high prevalence of BHS and increased
ASO titer despite antibiotic prophylaxis in the current
study is not explained by lack of susceptibility to penicil-
lin since no isolate was resistant to the drug in vitro. It
appears that the timing of the antibiotic prophylaxis is a
more significant factor. Children who received antibiotic
prophylaxis within 2-weeks of the last dose exhibited
significantly lower BHS culture positivity than those who
received four-weekly injection (p = 0. 02). There was no
statistically significant difference between 2- and 3-weeks
of injection although a trend could be observed in that a
higher percentage of participants showed more BHS
Table 3 Risk factors associated with BHS colonization of throat in children on antibiotic prophylaxis for RHD
Risk factors Beta-hemolytic streptococci
Culture positive Culture negative P-value
Agea 5–9 (n = 55) 13 42 0.4303
10–15 (n = 172) 40 132
Sexa Male (n = 95) 26 69 0.2758
Female (n =137) 29 108
Residence Urban (n = 121) 27 94 0.6302
Rural (n = 112) 28 84
Family size <6 (n = 139) 32 107 0.7990
≥7 (n = 94) 23 71
Missing at least one
prophylaxis within
last 6 months
Missing (n = 33) 16 17 0.0003
Not missing (n = 200) 39 161
Family history of
pharyngitis
Yes (n = 25) 5 20 0.7235
No (n = 203) 47 156
Family educational
statusa
Illiterate (n = 68) 18 50 0.4739
Literate (n = 163) 36 127
Uvulectomya Yes (n = 57) 16 41 0.3566
No (n = 159) 35 124
aMissed values were excluded from analysis
Table 4 Duration of interval between penicillin injections as risk factor for throat colonization with BHS
Interval between antibiotic prophylaxis Culture positive Culture negative OR (95 % CI) p-value
<16 days (n = 98) 15 83 1
17–21 days (n = 25) 5 20 1.4(0.5–4.3) 0.57
22–28 days (n = 50) 16 34 2.6(1.2–5.9) 0.02
≥29 days (n = 38) 15 23 3.6(1.5–8.5) 0.003
CI confidence interval, OR odds ratio
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culture positivity rate in the 3-week interval group. We
have not evaluated the dynamics of penicillin bioavailabil-
ity in our patients. Reduced serum penicillin G due to any
cause may lead to ineffective prophylaxis. This could be
due to poor quality of drugs as brands of penicillin pre-
scribed may vary in effectiveness [23], but it could also be
due to patient-specific factors. Some individuals have been
reported to degrade penicillin G in their serum faster than
others [18, 28]. This is obviously aggravated when the
interval of injection is longer.
Recurrence of RF and reduced ability of penicillin to
eradicate BHS are reported continuously from several
parts of the world, indicating failure of benzathine peni-
cillin G prophylaxis [18, 19, 29, 30]. A combination of
factors has to be considered in each particular setting
before an appropriate regimen is selected for the re-
spective population [19]. One major problem in second-
ary prophylaxis for RHD is compliance. In our series,
14.2 % of the participants had missed one or more injec-
tions within the last 6-months of follow up, and these
participants had a significantly higher BHS culture posi-
tivity rate (p = 0.0003) than others. We did not find any
significant association of factors such as age, sex, history
of family pharyngitis, uvulectomy and family educational
status with culture positivity of BHS or failure of regimen.
The BHS culture positivity rate (24.0 %) was similar to
a study conducted on chronic RHD patients about
25-years ago (20.45 %) (p = 0. 61) [6]. Although the
children had received on-going monthly penicillin G
prophylaxis this culture positivity rate was significantly
higher than that reported for healthy schoolchildren in
Addis Ababa by Abdissa and colleagues (17.7 %) (P = 0. 03)
[31]. It seems that Group F and G BHS were prominent in
the present study, a finding which is comparable with other
studies conducted elsewhere, such as in Mumbai where
Group C and G streptococcal disease burden was higher
than GAS among schoolchildren [2, 32]. Even though the
type of prophylaxis and the methodology is different, the
present finding showed a lower culture positivity rate as
compared with a carrier rate of 15.4 % GAS among 26 pa-
tients on once-weekly azithromycin (AZT), but higher than
22 patients taking oral penicillin (0 %) [33].
In addition to traditional methods (beta-hemolytic char-
acteristics, catalase test, gram stains and serogouping),
species identification was also performed by MALDI-TOF
MS. Among six GAS, four were S. pyogenes. The other 2
were bacitracin-resistant S. dysgalactiae subsp. equisimilis.
In the current study, S. dysgalactiae subsp. equisimilis pos-
sessing Lancefield group A, C and G were isolated. There
are reports that S. dysgalactiae subsp. equisimilis express-
ing Lancefield group A is on the rise as a pathogen [3, 34].
In the present study, four S. dysgalactiae subsp. equisimilis
were isolated from four RHD patients, raising a suspicion
whether these organisms are associated with RHD.
Pharyngeal Group C and G have often been detected
in patients with RF/RHD in endemic countries but
there is as yet no conclusive evidence whether these
organisms do cause acute RF as is known for Group
A strains [2, 6, 35, 36].
We observed that 3 BHS isolates and some alpha-
hemolytic streptococcal isolates including S. pneumoniae
were not correctly identified by MALDI-TOF MS speci-
ation (very small score value and inconsistent results).
Others have also observed that some strains were not
correctly identified by this method and that improve-
ments to this technique as well as complementary tests
are needed [37].
In the present study, all GAS isolates were susceptible
to penicillin, which is comparable with other studies
conducted in Ethiopia and elsewhere [31, 38]. Penicillin-
resistant GAS is not yet reported from this setting
[38, 39]. Penicillin non-susceptible S. agalactiae/
group B streptococcus and susceptible group G and F
streptococci were, however, observed in the present
study, which is in contrast with studies conducted
elsewhere [31, 32]. Penicillin and oxacillin susceptibil-
ity results were also discordant in this study.
In the present study, one GAS strain was erythromycin-
resistant and another one intermediately susceptible to
erythromycin. Erythromycin-resistant GAS strains are
emerging. Studies have reported proportions of 96.1 %
[39] and 38 % of GAS resistance to erythromycin [40].
One report high-lighted how macrolide treatment failure
in streptococcal pharyngitis resulted in acute RF [40].
Thus, these are indications that antimicrobial drug resist-
ance is emerging among BHS as well [32, 38]. For diag-
nostic purposes, the emerging bacitracin resistance S.
pyogenes should be noted [41].
Presumptive identification of BHS on blood agar is not
necessarily straight-forward. Human blood agar is not
recommended for BHS isolation [42, 43]. We observed,
as others have also experienced, that some alpha-
hemolytic streptococci are difficult to differentiate from
BHS, especially when the incubation time is extended to
48 h. Many of them were bacitracin susceptible (84.6 %
of S. parasanguinis, 54.5 % of S. mitis and 8 unclassified
others). In other studies, bacitracin susceptibility was re-
ported in some GCS and as high as 67 % among GGS
[44] and 12.2 % among non-group A BHS [45]. On the
other hand, bacitracin resistance S. pyogenes was re-
ported elsewhere [41]. This calls for improvements in
typing techniques in clinical laboratories in order to
monitor trends of RHD epidemiology and control.
Conclusion
A relatively high prevalence of BHS was detected among
RHD patients who were under secondary antibiotic
prophylaxis. S. pyogenes and S. dysgalactiae subsp.
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equisimilis were isolated from the throat together with
Group F and Group G streptococci. Therefore, the pres-
ence of GAS, GCS and GGS and increased ASO titer in-
dicating recent streptococcal infection might suggest
inadequate prophylaxis and may call for a review of the
regimen in use and a better monitoring of trends with
larger studies including bioavailability of penicillin lots
in use. Continuous health education to caretakers and
children regarding the importance of taking the ben-
zathine penicillin prophylaxis on time as prescribed is
recommended.
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